Abstracts tagged "methotrexate (MTX) and pediatric rheumatology"

Abstract Number: 2271 • 2017 ACR/ARHP Annual Meeting
Safety of Adalimumab±Methotrexate for the Treatment of Polyarticular Juvenile Idiopathic Arthritis (pJIA)
Hermine I. Brunner¹, Nicola Ruperto², Kabita Nanda³, Mary Toth⁴, Ivan Foeldvari⁵, John F. Bohnsack⁶, Diana Milojevic⁷, C. Egla Rabinovich⁸, Daniel J Kingsbury⁹, Katherine Marzan¹⁰, Pierre Quartier¹¹, Kirsten Minden¹², Elizabeth Chalom¹, Gerd Horneff¹³, Rolf M. Kuester¹⁴, Jason A Dare¹⁵, Mareike Bereswill¹⁶, Jasmina Kalabic¹⁶, Hartmut Kupper¹⁶, Daniel J Lovell¹ and Alberto Martini², ¹PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²PRINTO-IRCCS Gaslini, Genova, Italy, ³University of Washington School of Medicine and Seattle Children's Hospital, Bayside, NY, ⁴Akron Children's Hospital, Akron, OH, ⁵Department of Pediatric Rheumatology, Hamburger Zentrum für Kinder und Jugendrheumatologie, Hamburg, Germany, ⁶University of Utah, Department of Pediatrics, Salt Lake City, UT, ⁷The Floating Hospital for Children at Tufts Medical Center, Boston, MA, ⁸Duke University Medical Center, Durham, NJ, ⁹Randall Children’s Hospital at Legacy Emanuel, Portland, OR, ¹⁰Children's Hospital Los Angeles, Los Angeles, CA, ¹¹Hopital Necker-Enfants Malades, Paris, France, ¹²Kinderklinik der Charite, Otto-Heubner Centrum, Berlin, Germany, ¹³Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, ¹⁴Orthopädiezentrum Altona, Hamburg, Germany, ¹⁵Arkansas Children’s Hospital, Little Rock, AR, ¹⁶AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany
Background/Purpose: JIA is the most common chronic inflammatory rheumatic disease of childhood. Due to their known safety and efficacy, TNF inhibitors are used for long-term…
Abstract Number: 2001 • 2012 ACR/ARHP Annual Meeting
Methotrexate and Injectable Tumor Necrosis Factor Alpha Inhibitor Adherence and Persistence in Children with Rheumatic Diseases
Sarah Ringold¹, Shannon Grant², Charmaine Girdish³, Carol A. Wallace⁴ and Sean Sullivan⁵, ¹Pediatrics, Seattle Children's Hospital/Univ of Washington, Seattle, WA, ²Axio Research LLC, Seattle, WA, ³Research, CVS Caremark, Scottsdale, AZ, ⁴Pediatrics, Seattle Childrens Hospital, Seattle, WA, ⁵Health Sciences Building, University of Washington, Seattle, WA
Background/Purpose: Medication adherence and persistence have been demonstrated to have important implications for treatment effectiveness, cost, and safety. Methotrexate is one of the most commonly…
Abstract Number: 1151 • 2012 ACR/ARHP Annual Meeting
Low-Dose Methotrexate and the Selective Accumulation of Intracellular Aminoimidazolecarboxamide Ribotide
Ryan S. Funk¹, Leon van Haandel¹, Mara L Becker² and J.S. Leeder¹, ¹Clinical Pharmacology and Medical Toxicology, Children's Mercy Hospital, Kansas City, MO, ²Clinical Pharmacology and Rheumatology, Children's Mercy Hospital, Kansas City, MO
Background/Purpose: Current evidence suggests that the anti-folate methotrexate (MTX) mediates its anti-inflammatory effects through inhibition of the purine synthesis pathway causing the accumulation of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].